Overview: Total PSA/Free PSA Ratio Marker Rapid TestIntroduction: The Total PSA/Free PSA Ratio Marker Rapid Test is a diagnostic tool designed to detect total PSA and free PSA levels in serum or plasma samples, facilitating the screening of prostate cancer. Associated with prostate adenocarcinoma, this oncologic condition presents with urinary issues, pelvic pain, and severe complications like metastasis if untreated, particularly in older men or those with family history. Per the 2023 American Urological Association guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in clinical pathology settings. This rapid diagnostic falls under clinical pathology and targets individuals with urologic or systemic symptoms, addressing the challenge of early detection to guide prostatectomy or radiation therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: PSA Ratio Rapid Test.FDA Status: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Beckman Coulter, this test advanced prostate marker detection, providing a rapid alternative to traditional assays.Purpose: The test screens for Total PSA/Free PSA ratio to guide prostate cancer diagnosis, assess tumor status, and inform treatment and prevention strategies.Test Parameters: Presence of Total PSA and Free PSA, detected with reasonable specificity to indicate cancer activity, typically detectable in serum or plasma at abnormal ratios during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report urinary issues, pelvic pain, or recent prostate exams.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on urinary issues, pelvic pain, prior prostate issues, or family history of oncologic disease, as well as any recent trauma or treatments.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated cancer including metastasis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent prostate manipulation can affect results. Correlation with biopsy or imaging is recommended to confirm findings.Clinical Significance: A positive result indicates possible prostate cancer, necessitating further investigation like biopsy or urology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.Specialist Consultation: Urologists or oncologists should be consulted for case management, treatment planning, and coordination with cancer programs.Additional Supporting Tests: Biopsy, DRE, or MRI for confirmation.Test Limitations: The test may produce false positives in benign hypertrophy or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AUA Guidelines 2023, Journal of Urology 2024, Pathology 2025.